These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 12723747)
1. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Henry D; McGettigan P Int J Clin Pract Suppl; 2003 Apr; (135):43-9. PubMed ID: 12723747 [TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. Biskupiak JE; Brixner DI; Howard K; Oderda GM J Pain Palliat Care Pharmacother; 2006; 20(3):7-14. PubMed ID: 16931473 [TBL] [Abstract][Full Text] [Related]
3. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Bollini P; García Rodríguez LA; Pérez Gutthann S; Walker AM Arch Intern Med; 1992 Jun; 152(6):1289-95. PubMed ID: 1534651 [TBL] [Abstract][Full Text] [Related]
4. Risk of upper gastrointestinal events with the use of various NSAIDs: a case-control study in a general population. Helin-Salmivaara A; Saarelainen S; Grönroos JM; Vesalainen R; Klaukka T; Huupponen R Scand J Gastroenterol; 2007 Aug; 42(8):923-32. PubMed ID: 17613921 [TBL] [Abstract][Full Text] [Related]
6. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. Price-Forbes AN; Callaghan R; Allen ME; Rowe IF Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035 [TBL] [Abstract][Full Text] [Related]
7. Long-term NSAID use in primary care: changes over a decade and NICE risk factors for gastrointestinal adverse events. Thompson PW; Tee L; McBride J; Quincey D; Strat Liddiard G Rheumatology (Oxford); 2005 Oct; 44(10):1308-10. PubMed ID: 15972345 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Huang WF; Hsiao FY; Wen YW; Tsai YW Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003 [TBL] [Abstract][Full Text] [Related]
11. Upper gastrointestinal complications associated with NSAIDs in children. Autret-Leca E; Bensouda-Grimaldi L; Maurage C; Jonville-Bera AP Therapie; 2007; 62(2):173-6. PubMed ID: 17582320 [TBL] [Abstract][Full Text] [Related]
12. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Lanas A; Ferrandez A Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792 [TBL] [Abstract][Full Text] [Related]
13. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747 [TBL] [Abstract][Full Text] [Related]
14. [Nonsteroidal-anti-inflammatory drugs and serious undesirable gastrointestinal effects]. Fabijanić D; Kardum D; Banić M; Fabijanić A Lijec Vjesn; 2007; 129(6-7):205-13. PubMed ID: 18018712 [TBL] [Abstract][Full Text] [Related]
15. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections? McCarthy DM Eur J Surg Suppl; 2002; (587):89-99. PubMed ID: 16144207 [TBL] [Abstract][Full Text] [Related]
16. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines. Moride Y; Ducruet T; Boivin JF; Lavoie F; Rochon S Can J Clin Pharmacol; 2005; 12(2):e201-11. PubMed ID: 15998959 [TBL] [Abstract][Full Text] [Related]
17. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523 [TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. Moore RA; Derry S; Phillips CJ; McQuay HJ BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784 [TBL] [Abstract][Full Text] [Related]
19. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734 [TBL] [Abstract][Full Text] [Related]
20. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Lanas A; Hunt R Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]